Free tool
FAERS Monitor: Premarin
Last checked: Nov 21, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 020216 or its brand name (Premarin, Estrogens, Conjugated). Reports on generic versions are filed under their own applications.
Reports
59,395
Serious
42,092
71% of reports
Hospitalization
9,554
Death reported
1,858
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- breast cancer9,645
- breast cancer female8,869
- drug ineffective3,460
- nausea2,431
- headache2,389
- pain2,320
- fatigue2,294
- off label use2,238
- dizziness1,698
- breast cancer metastatic1,682
- dyspnoea1,670
- malaise1,620
- diarrhoea1,572
- arthralgia1,504
- anxiety1,451
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4,156 |
| 2005 | 3,642 |
| 2006 | 3,215 |
| 2007 | 1,690 |
| 2008 | 3,636 |
| 2009 | 5,174 |
| 2010 | 9,123 |
| 2011 | 2,686 |
| 2012 | 2,586 |
| 2013 | 2,158 |
| 2014 | 2,056 |
| 2015 | 2,473 |
| 2016 | 2,564 |
| 2017 | 1,999 |
| 2018 | 1,802 |
| 2019 | 2,168 |
| 2020 | 2,307 |
| 2021 | 1,531 |
| 2022 | 1,415 |
| 2023 | 1,088 |
| 2024 | 857 |
| 2025 | 644 |
| 2026 | 420 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 20,994,764 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| breast cancer femaleSignal | 8,869 | 175.4 | 171.2 | 1,029,206 |
| breast cancer metastaticSignal | 1,682 | 65.6 | 62.3 | 90,254 |
| breast cancerSignal | 9,645 | 40.8 | 40.0 | 336,831 |
| anxiety | 1,451 | 1.8 | 1.7 | 529 |
| headache | 2,389 | 1.4 | 1.3 | 223 |
| pain | 2,320 | 1.3 | 1.3 | 204 |
| malaise | 1,620 | 1.3 | 1.2 | 120 |
| arthralgia | 1,504 | 1.3 | 1.2 | 95 |
| dizziness | 1,698 | 1.2 | 1.2 | 61 |
| nausea | 2,431 | 1.1 | 1.0 | 18 |
| dyspnoea | 1,670 | 1.0 | 1.0 | 3 |
| fatigue | 2,294 | 1.0 | 1.0 | 4 |
| drug ineffective | 3,460 | 0.9 | 0.9 | 20 |
| off label use | 2,238 | 0.9 | 0.9 | 23 |
| diarrhoea | 1,572 | 0.9 | 0.8 | 36 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.